Compare USNA & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | EDIT |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.1M | 432.8M |
| IPO Year | 1996 | 2016 |
| Metric | USNA | EDIT |
|---|---|---|
| Price | $22.71 | $2.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.30 |
| AVG Volume (30 Days) | 97.6K | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $1,060,902,000.00 | $31,937,000.00 |
| Revenue This Year | $3.90 | N/A |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | $54.70 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $16.60 | $1.66 |
| 52 Week High | $38.32 | $4.54 |
| Indicator | USNA | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 42.48 |
| Support Level | $18.71 | $2.77 |
| Resistance Level | $22.64 | $3.27 |
| Average True Range (ATR) | 1.01 | 0.26 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 85.97 | 10.50 |
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.